After putting in evidence the efficiency of an IN administration of PACAP for stroke treatment and the existence of a therapeutic window of a least 6 h in the tMCAO mice model, we looked for the most efficient dose of the peptide. This evidence concerns the gene ADCYAP1 and stroke disorder.